ArticleMedical care2013
Validation of electronic data on chemotherapy and hormone therapy use in HMOs.
Article in Medical care, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 37 citations in OpenAlex.
- Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study.International journal of cancer · 2025Article
- Association of systemic therapy with survival among adults with advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- The development and use of data warehousing in clinical settings: a scoping review.Frontiers in digital health · 2025Review
- Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.Cancer treatment and research communications · 2023Article
- Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients treated at the University Hospital of Siena for onco-haematological indications.Frontiers in oncology · 2023Article
- Accuracy of tumor registry versus pharmacy dispensings for breast cancer adjuvant endocrine therapy.Cancer causes & control : CCC · 2022Article
- Developing an algorithm across integrated healthcare systems to identify a history of cancer using electronic medical records.Journal of the American Medical Informatics Association : JAMIA · 2022Article
- The Adolescent and Young Adult (AYA) Horizon Study: An AYA Cancer Survivorship Cohort.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Real-world Clinical Implementation of Lung Cancer Screening-Evaluating Processes to Improve Screening Guidelines-Concordance.Journal of general internal medicine · 2020Article
- Melanoma incidence, recurrence, and mortality in an integrated healthcare system: A retrospective cohort study.Cancer medicine · 2019Article
- Hospitalization Risk During Chemotherapy for Advanced Cancer: Development and Validation of Risk Stratification Models Using Real-World Data.JCO clinical cancer informatics · 2019Article
- Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Medical Care Costs for Recurrent versus De Novo Stage IV Cancer by Age at Diagnosis.Health services research · 2018Article
- Detecting Lung and Colorectal Cancer Recurrence Using Structured Clinical/Administrative Data to Enable Outcomes Research and Population Health Management.Medical care · 2017Article
- Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data.JCO clinical cancer informatics · 2017Article
- Survival after recurrence of stage I-III breast, colorectal, or lung cancer.Cancer epidemiology · 2017Article
- Optimizing patient-reported outcome and risk factor reporting from cancer survivors: a randomized trial of four different survey methods among colorectal cancer survivors.Journal of cancer survivorship : research and practice · 2017Article
- Predicting neutropenia risk in patients with cancer using electronic data.Journal of the American Medical Informatics Association : JAMIA · 2017Article
- Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer.Clinical lung cancer · 2017Article
- Comparison of SEER Treatment Data With Medicare Claims.Medical care · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundMost data regarding medical care for cancer patients in the United States comes from Surveillance, Epidemiology and End Results-linked Medicare analyses of individuals aged 65 years or older and typically excludes Medicare Advantage enrollees.
objectivesTo assess the accuracy of chemotherapy and hormone therapy treatment data available through the Cancer Research Network's Virtual Data Warehouse (VDW). RESEARCH
designRetrospective, longitudinal cohort study. Medical record-abstracted, tumor registry-indicated treatments (gold standard) were compared with VDW-indicated treatments derived from health maintenance organization pharmacy, electronic medical record, and claim-based data systems. SUBJECTS: Enrollees aged 18 years and older diagnosed with incident breast, colorectal, lung, or prostate cancer from 2000 through 2007. MEASURES: Sensitivity, specificity, and positive predictive value were computed at 6 and 12 months after cancer diagnosis.
resultsApproximately 45% of all cancer cases (total N=23,800) were aged 64 years or younger. Overall chemotherapy sensitivity/specificities across the 3 health plans for incident breast, colorectal, lung, and prostate cancer cases were 95%/90%, 95%/93%, 93%/93%, and 85%/77%, respectively. With the exception of prostate cancer cases, overall positive predictive value ranged from 86% to 89%. Small variations in chemotherapy data accuracy existed due to cancer site and data source, whereas greater variation existed in hormone therapy capture across sites.
conclusionsStrong concordance exists between gold standard tumor registry measures of chemotherapy receipt and Cancer Research Network VDW data. Health maintenance organization VDW data can be used for a variety of studies addressing patterns of cancer care and comparative effectiveness research that previously could only be conducted among elderly Surveillance, Epidemiology and End Results-Medicare populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.